Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy

Naval Daver, Theresa Liu Dumlao, Farhad Ravandi, Sherry Pierce, Gautam Borthakur, Naveen Pemmaraju, Aziz Nazha, Stefan Faderl, Elias Jabbour, Guillermo Garcia-Manero, Jorges Cortes, Hagop Kantarjian, Alfonso Quintás-Cardama

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Background: The effect of prognostically important gene mutations (MUTs), nucleophosmin (nucleolar phosphoprotein B23, numatrin) (NPM1) and fms-related tyrosine kinase 3 (FLT3), in elderly patients with acute myeloid leukemia (AML) is not well defined. Patients and Methods: We analyzed 557 patients, 65 years of age or older with newly diagnosed AML, treated at our institution between 2000 and 2010 with cytotoxic chemotherapy. NPM1 and FLT3 analysis were available in 146 patients (26%) and 388 patients (70%), respectively. Results: NPM1 and FLT3 MUTs occurred in 16% and 12% of patients, respectively. No difference in median overall survival was observed between FLT3-MUT and NPM1-MUT patients who received cytotoxic chemotherapy. Outcome was significantly better among patients with NPM1-MUT/FLT3-wild type (WT) genotype (n = 14) compared with patients carrying FLT3/NPM1 genotypes other than NPM1-MUT/FLT3-WT (n = 125). The complete remission rates were 71% and 49%, respectively (P =.11). The median survival was 21.5 months vs. 9.0 months and estimated 2-year survival rates were 51% vs. 38%, respectively (P =.003). NPM1 and FLT3 MUTs appear to occur less frequently in elderly AML patients. The prognostic effect of isolated NPM1- or isolated FLT3-MUT is minimal. Conclusion: Elderly AML patients with NPM1-MUT/FLT3-WT genotype have significantly improved outcomes compared with patients with other NPM1/FLT3 genotypes when treated with cytotoxic chemotherapy.

Original languageEnglish (US)
Pages (from-to)435-440
Number of pages6
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number4
StatePublished - Aug 2013
Externally publishedYes


  • Acute myeloid leukemia
  • Cytotoxic chemotherapy
  • Elderly
  • FLT3
  • NPM1

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy'. Together they form a unique fingerprint.

Cite this